Summary

Market Size & Trends

The Middle East human papilloma virus testing market size was estimated at USD 60.02 million in 2024 and is projected to reach USD 203.37 million by 2033, growing at a CAGR of 14.80% from 2025 to 2033. Low HPV vaccine awareness and acceptance in the Middle East, driven by limited inclusion in national immunization programs, creates a stronger reliance on testing for early detection. Government-led screening campaigns, women’s health initiatives, and expansion of diagnostic infrastructure are supporting growth. Advancements in molecular diagnostics and self-collection technologies, even if not yet regionally approved, are influencing adoption strategies through pilot programs and private sector offerings. While cervical cancer incidence remains below global averages, changing demographics, evolving sexual behaviors, and cultural barriers to vaccination are prompting policymakers and healthcare providers to invest in HPV testing as a proactive measure to mitigate future disease burden.

The industry is evolving, shaped by policy initiatives, technology adoption, and varying levels of public awareness. While cervical cancer incidence in most countries remains below global averages, growing recognition of HPV’s broader health impact is prompting gradual expansion of screening and vaccination programs. Regional meta-analyses indicate that HPV vaccine awareness averages in the low 40% range, with higher levels in countries where the vaccine is part of the national immunization schedule. For example, Israel’s longstanding program reports awareness levels above 80%, whereas in markets without formal inclusion-such as Palestine-awareness remains extremely low. Within the Gulf Cooperation Council (GCC), countries such as the UAE and Saudi Arabia show higher awareness and acceptance, aligned with more structured public health interventions.

Middle East Human Papilloma Virus Testing Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East human papilloma virus testing market report on the basis of application, product, technology, end use, and country:

• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Cervical Cancer Screening
• Vaginal Cancer Screening
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
• Consumables
• Services
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• PCR
• Immunodiagnostics
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Laboratories
• Others
• Country Outlook (Revenue, USD Million, 2021 - 2033)
• Saudi Arabia
• UAE
• Kuwait
• Qatar
• Oman

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Application
1.2.2. Product
1.2.3. Technology
1.2.4. End Use
1.2.5. Regional Scope
1.2.6. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Application Outlook
2.2.2. Product Outlook
2.2.3. Technology Outlook
2.2.4. End Use Outlook
2.2.5. Regional Outlook
2.3. Competitive Scenario
Chapter 3. ME Human Papilloma Virus (HPV) Testing Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. ME Human Papilloma Virus (HPV) Testing Market Analysis Tools
3.3.1. Industry Analysis – Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
Chapter 4. ME Human Papilloma Virus (HPV) Testing Market: Application Estimates & Trend Analysis
4.1. Application Segment Dashboard
4.2. ME Human Papilloma Virus (HPV) Testing Market: Application Movement Analysis
4.3. ME Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By Application, 2021 to 2033 (USD Million)
4.4. Cervical Cancer Screening
4.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
4.5. Vaginal Cancer Screening
4.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 5. ME Human Papilloma Virus (HPV) Testing Market: Product Estimates & Trend Analysis
5.1. Product Segment Dashboard
5.2. ME Human Papilloma Virus (HPV) Testing Market: Product Movement Analysis
5.3. ME Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By Product, 2021 to 2033 (USD Million)
5.4. Instruments
5.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
5.5. Consumables
5.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
5.6. Services
5.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 6. ME Human Papilloma Virus (HPV) Testing Market: Technology Estimates & Trend Analysis
6.1. Technology Segment Dashboard
6.2. ME Human Papilloma Virus (HPV) Testing Market: Technology Movement Analysis
6.3. ME Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By Technology, 2021 to 2033 (USD Million)
6.4. PCR
6.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
6.5. Immunodiagnostics
6.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
6.6. Others
6.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 7. ME Human Papilloma Virus (HPV) Testing Market: End Use Estimates & Trend Analysis
7.1. End Use Segment Dashboard
7.2. ME Human Papilloma Virus (HPV) Testing Market: End Use Movement Analysis
7.3. ME Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By End Use, 2021 to 2033 (USD Million)
7.4. Hospitals & Clinics
7.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
7.5. Laboratories
7.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
7.6. Others
7.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 8. ME Human Papilloma Virus (HPV) Testing Market: Regional Estimates & Trend Analysis
8.1. Regional Market Dashboard
8.2. Regional Market Share Analysis, 2024 & 2033
8.3. ME Human Papilloma Virus (HPV) Testing Market by Region: Key Takeaways
8.4. Middle East
8.4.1. Middle East Market Estimates and Forecasts 2021 to 2033 (USD Million)
8.4.2. Saudi Arabia
8.4.2.1. Key Country Dynamics
8.4.2.2. Regulatory Framework/ Reimbursement Structure
8.4.2.3. Competitive Scenario
8.4.2.4. Saudi Arabia Market Estimates and Forecasts 2021 to 2033 (USD Million)
8.4.3. UAE
8.4.3.1. Key Country Dynamics
8.4.3.2. Regulatory Framework/ Reimbursement Structure
8.4.3.3. Competitive Scenario
8.4.3.4. UAE Market Estimates and Forecasts 2021 to 2033 (USD Million)
8.4.4. Kuwait
8.4.4.1. Key Country Dynamics
8.4.4.2. Regulatory Framework/ Reimbursement Structure
8.4.4.3. Competitive Scenario
8.4.4.4. Kuwait Market Estimates and Forecasts 2021 to 2033 (USD Million)
8.4.5. Oman
8.4.5.1. Key Country Dynamics
8.4.5.2. Regulatory Framework/ Reimbursement Structure
8.4.5.3. Competitive Scenario
8.4.5.4. QatarMarket Estimates and Forecasts 2021 to 2033 (USD Million)
8.4.6. Qatar
8.4.6.1. Key Country Dynamics
8.4.6.2. Regulatory Framework/ Reimbursement Structure
8.4.6.3. Competitive Scenario
8.4.6.4. QatarMarket Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/ Competition Categorization
9.3. Vendor Landscape
9.3.1. Key Company Heat Map Analysis, 2024
9.4. Company Profiles
9.4.1. Abbott
9.4.1.1. Company Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. Biomedical Diagnostics
9.4.2.1. Company Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. bioMerieux
9.4.3.1. Company Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. Bio-Rad Laboratories, Inc.
9.4.4.1. Company Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. Fujirebio
9.4.5.1. Company Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Oncolab
9.4.6.1. Company Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. Hologic, Inc.
9.4.7.1. Company Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. Qiagen
9.4.8.1. Company Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. F. Hoffmann-La Roche Ltd
9.4.9.1. Company Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Strategic Initiatives
9.4.10. Siemens Healthineers AG
9.4.10.1. Company Overview
9.4.10.2. Financial Performance
9.4.10.3. Product Benchmarking
9.4.10.4. Strategic Initiatives